CL vs CUE · P/E 34, rev $20.38B vs rev $9.3M
Colgate-Palmolive Company (CL) versus Cue Biopharma (CUE) — a side-by-side from cached financials, not a winner call.
Colgate-Palmolive Company (CL) is a household & personal products company listed on US.
Cue Biopharma (CUE) is a biotechnology company listed on US.
Latest reported CL revenue for 2025-12-31 was $20.38B. Net income was $2.13B. Revenue was up 1.4% from 2024-12-31 to 2025-12-31. CL currently screens at market cap $70.88B and trailing P/E 34.3.
Latest reported CUE revenue for 2024-12-31 was $9.3M. Net income was -$40.7M. Revenue was up 69.2% from 2023-12-31 to 2024-12-31. CUE currently screens at market cap $59.5M.
CL currently screens at market cap $70.88B and trailing P/E 34.3. CUE currently screens at market cap $59.5M.
Not investment advice. Open the CL and CUE stock pages for the full models.
Not investment advice.